ASPET Award for Experimental Therapeutics

ASPET Award for Experimental Therapeutics is a prestigious scientific honor presented by the American Society for Pharmacology and Experimental Therapeutics (ASPET). It recognizes individuals for seminal contributions to the discovery and characterization of novel therapeutic agents, bridging the gap between basic pharmacological research and clinical application. The award underscores the critical role of translational science in advancing modern medicine and improving patient outcomes. It is considered one of the highest accolades within the field of pharmacology and experimental therapeutics.

History and background

The award was established in 2008, reflecting a growing emphasis within the biomedical community on translating fundamental discoveries into effective treatments. Its creation was influenced by the broader initiatives of the National Institutes of Health, particularly the NIH Roadmap for Medical Research, which prioritized translational science. The American Society for Pharmacology and Experimental Therapeutics, founded in 1908 at Johns Hopkins University, has a long history of honoring scientific excellence through awards like the Goodman and Gilman Award in Drug Receptor Pharmacology. The establishment of this specific award aligned with societal goals to highlight and incentivize research that directly impacts drug development and therapeutic strategies against diseases such as cancer, cardiovascular disease, and neurodegenerative disorders.

Award criteria and eligibility

Eligibility for the award is restricted to scientists who are members of the American Society for Pharmacology and Experimental Therapeutics and have made distinguished, sustained contributions to experimental therapeutics. The primary criterion is the demonstration of a direct link between basic pharmacological research and the development of novel therapeutic agents or strategies. This includes work leading to new FDA-approved drugs, significant advancements in clinical trial design, or the elucidation of mechanisms that have reshaped treatment paradigms. Contributions can span various domains, including but not limited to medicinal chemistry, pharmacokinetics, toxicology, and clinical pharmacology. The award committee places high value on research that has demonstrably influenced medical practice.

Notable recipients

The roster of awardees includes many luminaries in pharmacology and drug discovery. Early recipients include **Raymond L. Woosley** (2008), recognized for his work on drug-induced torsades de pointes and the founding of the CERTs program. **Paul A. Insel** (2009) was honored for his research on G protein-coupled receptors and autonomic pharmacology. **Robert J. Lefkowitz** (2010), later a recipient of the Nobel Prize in Chemistry, was awarded for his groundbreaking studies on adrenergic receptors. More recent honorees include **John L. Wallace** (2017) for his contributions to gastrointestinal pharmacology and the development of NO-NSAIDs, and **Kathleen M. Giacomini** (2019) for her research on membrane transporters and their role in drug response. The 2023 award was presented to **Michael J. Welsh** for his transformative research on cystic fibrosis therapeutics.

Selection process

The selection is conducted by a dedicated award committee appointed by the American Society for Pharmacology and Experimental Therapeutics Council. The process begins with an open nomination period where any ASPET member can submit a candidate's dossier, including a detailed letter of nomination, the nominee's curriculum vitae, and supporting letters. The committee, composed of senior experts in experimental therapeutics and translational research, rigorously evaluates each nomination against the award's criteria. Deliberations focus on the significance, innovation, and tangible impact of the nominee's body of work. The final recommendation is ratified by the ASPET Council, and the award is presented at the society's annual meeting, often held in conjunction with the Experimental Biology conference.

Significance and impact

The award holds substantial significance within the global biomedical research community. It serves as a powerful symbol of the essential bridge between laboratory science and the clinic, encouraging young scientists to pursue careers in translational pharmacology. By highlighting successful drug discovery trajectories, such as those leading to therapies for HIV/AIDS, hepatitis C, and multiple sclerosis, the award educates the public and policymakers about the value of sustained investment in basic and applied research. Furthermore, it reinforces the central role of the American Society for Pharmacology and Experimental Therapeutics in shaping the future of medicine and fosters collaboration across disciplines like molecular biology, genomics, and clinical medicine.

Category:American Society for Pharmacology and Experimental Therapeutics Category:Medical and health awards Category:Pharmacology awards